secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001113148-23-000014
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharma receives Nasdaq deficiency for Minimum MVPHS; faces multiple delisting risks
--------------------------------------------------------------------------------

- Nasdaq letter on Sep 5: MVPHS < $15M for prior 30 consecutive business days.
- Company has 180 calendar days, until Mar 4, 2024, to regain compliance.
- Already out of compliance with bid-price (Rule 5450(a)(1)) and MVLS (Rule 5450(b)(2)(A)) listing rules.
- Existing appeal of prior delisting determination is pending before Nasdaq Panel.
- Failure to cure MVPHS could lead to delisting or transfer to Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000111314823000014/0001113148-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000111314823000014/infi-20230905.htm
  HTML page:      https://secwatch.observer/filing/0001113148-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer